This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu
Actor Portrayal

Common administration and CPT codes for for M-M-R®II (Measles, Mumps, & Rubella Virus Vaccine Live)

Vaccines for Children Program1

M-M-R®II is available through the Vaccines for Children (VFC) Program for children who qualify. Check with your state or local VFC Program to learn more about the specific products available to your practice.

CPT and ICD-10-CM Codes

Below are the CPT Product and Administration codes as set forth in the Current Procedural Terminology. Plan coding requirements may vary, so it is important to check with each payer as to payer-specific requirements. For claim submission procedures regarding government programs (eg, Medicare or Medicaid), contact the appropriate program representative.

CPT Code for M-M-R®II2

CPT codeProduct code
90707M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

Vaccine administration codes3

CPT codeProduct code
90460Product administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each product or toxoid component administered (Do not report with 90471 or 90473)
+90461Product administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional product or toxoid component administered
90471Product administration, one injection of any vaccine that is not accompanied by face-to-face physician or qualified health care professional counseling to the patient/family (Do not report with 90460 or 90473)
+90472Product administration, each additional injection of any vaccine that is not accompanied by face-to-face physician or qualified health care professional counseling to the patient/family (Do not report with 90460 or 90473)
There can be only 1 first administration during a given visit.
ICD-10-CM Code4
Z23
Effective for dates of service on or after October 1, 2024, encounter for immunization.

Remember, plan coding requirements vary

Plan coding requirements may vary, so it is important to check with each plan as to plan-specific requirements. For claim submission procedures regarding government programs (eg, Medicaid), contact the appropriate program representative.

ICD-10-CM, International Classification of Diseases and Related Health Problems, Tenth Revision, Clinical Modification.

CPT, Current Procedural Terminology.

CPT is a registered trademark of the American Medical Association.

References

  1. Centers for Disease Control and Prevention. Current CDC Vaccine Price List. Updated October 6, 2025. Accessed October 22, 2025. https://www.cdc.gov/vaccines-for-children/php/awardees/current-cdc-vaccine-price-list.html
  2. Centers for Disease Control and Prevention. Immunization information systems (IIS). CPT codes mapped to CVX codes.Last reviewed September 18, 2025. Accessed October 22, 2025. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt
  3. American Academy of Pediatrics. Coding for pediatric preventive care, 2025. Accessed October 22, 2025. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf
  4. Centers for Medicare & Medicaid Services (U.S.). ICD-10-CM Official Guidelines for Coding and Reporting FY 2025. Updated October 1, 2024. Accessed October 22, 2025. https://stacks.cdc.gov/view/cdc/158747

Indications and Usage

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and administration

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.

M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

Indications and Usage
Selected Safety Information

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and administration

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.

M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.